Mescaline is under clinical development by Mind Medicine MindMed and currently in Phase I for Unspecified Psychiatric Disorders. According to GlobalData, Phase I drugs for Unspecified Psychiatric Disorders have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mescaline’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mescaline overview
Mescaline is under development for the treatment of unspecified psychiatric disorders. It acts by targeting 5HT2A receptor.
Mind Medicine MindMed overview
Mind Medicine MindMed (MindMed) is a pharmaceutical drug development and clinical research company. It develops medicinal products to treat brain health disorders, psychiatry, pain and substance use disorders, and related therapeutic areas. The company’s product offerings include psychedelic and empathogen drugs. MindMed offers research and development supports such as non-clinical, pre-clinical, human clinical trials and investigator-initiated trials. It also develops drugs support clinical data opportunity in autism spectrum disorders (ASD), address a critical gap in opioid use disorder (OUD) treatment. MindMed is headquartered in New York city, New York, the US.
For a complete picture of Mescaline’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
